Phentermine-Topiramate Outcomes in Children with Duchenne Muscular Dystrophy, 2015-2025

From January 2015 to April 2025, this supplementary material reports clinical outcomes for six boys with Duchenne muscular dystrophy and obesity treated with phentermine-topiramate at Children's Hospital Colorado. It includes longitudinal data on BMI, weight, and cardiac parameters over treatment courses ranging from 0.6 to 4.2 years. The document was authored by figshare admin karger and is licensed under CC-BY-4.0.

Use Cases

• Analyzing BMI and weight standard deviation trends over time based on the reported longitudinal data.
• Investigating cardiac safety profiles of weight-loss medication in a high-risk pediatric population based on heart rate and blood pressure parameters.
• Assessing the incidence and types of adverse events, such as kidney stones, associated with long-term therapy.

Strengths

• Includes longitudinal data spanning up to 4.2 years of treatment.
• Reports specific median changes in BMI (-3.75 kg/m² in first year) and cardiac parameters (+13.5 bpm heart rate).
• Focuses on a specific, understudied population of six boys with Duchenne muscular dystrophy.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small in scale at 780.1 KB, representing a limited case series.

Provenance

Source

Children's Hospital Colorado

Collection Method

Clinical case series reporting.

Time Range

January 2015 to April 2025

Freshness

Last updated 2026-05-18 05:55:12; freshness should be verified.

Geography

United States (Colorado)